Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
Authors:
- Michael SchenkerMSMichael Schenker
- Mauricio BurottoMBMauricio Burotto
- Martin RichardetMRMartin Richardet
- Tudor-Eliade CiuleanuTCTudor-Eliade Ciuleanu
- Anthony GonçalvesAnthony Gonçalves
- Neeltje SteeghsNSNeeltje Steeghs
- Patrick SchoffskiPSPatrick Schoffski
- Paolo A AsciertoPAPaolo A Ascierto
- Michele MaioMMMichele Maio
- Iwona LugowskaILIwona Lugowska
- Lorena LupinacciLLLorena Lupinacci
- Alexandra LearyALAlexandra Leary
Open Access
- 6 August 2024
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (8) , e008872-11
Abstract
Background: Checkpoint inhibitor therapy has demonstrated overall survival benefit in multiple tumor types. Tumor mutational burden (TMB) is a predictive biomarker for response to immunotherapies. This study evaluated the efficacy of nivolumab+ipilimumab in multiple tumor types based on TMB status evaluated using either tumor tissue (tTMB) or circulating tumor DNA in the blood (bTMB). Patients and methods: Patients with metastatic or unresectable solid tumors with high (≥10 mutations per megabase) tTMB (tTMB-H) and/or bTMB (bTMB-H) who were refractory to standard therapies were randomized 2:1 to receive nivolumab+ipilimumab or nivolumab monotherapy in an open-label, phase 2 study (CheckMate 848; NCT03668119). tTMB and bTMB were determined by the Foundation Medicine FoundationOne® CDx test and bTMB Clinical Trial Assay, respectively. The dual primary endpoints were objective response rate (ORR) in patients with tTMB-H and/or bTMB-H tumors treated with nivolumab+ipilimumab. Results: In total, 201 patients refractory to standard therapies were randomized: 135 had tTMB-H and 125 had bTMB-H; 82 patients had dual tTMB-H/bTMB-H. In patients with tTMB-H, ORR was 38.6% (95% CI 28.4% to 49.6%) with nivolumab+ipilimumab and 29.8% (95% CI 17.3% to 44.9%) with nivolumab monotherapy. In patients with bTMB-H, ORR was 22.5% (95% CI 13.9% to 33.2%) with nivolumab+ipilimumab and 15.6% (95% CI 6.5% to 29.5%) with nivolumab monotherapy. Early and durable responses to treatment with nivolumab+ipilimumab were seen in patients with tTMB-H or bTMB-H. The safety profile of nivolumab+ipilimumab was manageable, with no new safety signals. Conclusions: Patients with metastatic or unresectable solid tumors with TMB-H, as determined by tissue biopsy or by blood sample when tissue biopsy is unavailable, who have no other treatment options, may benefit from nivolumab+ipilimumab. Trial registration number: NCT03668119.Keywords
Funding Information
- Bristol Myers Squibb (N/A)
This publication has 34 references indexed in Scilit:
- Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanomaCancer Medicine, 2022
- The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysisTranslational Oncology, 2022
- Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid TumorsJAMA Network Open, 2020
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studyThe Lancet Oncology, 2020
- Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor typesAnnals of Oncology, 2020
- Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung CancerMolecular Diagnosis & Therapy, 2019
- Tumor mutational load predicts survival after immunotherapy across multiple cancer typesNature Genetics, 2019
- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung CancerCancer Cell, 2018
- Mutational landscape and significance across 12 major cancer typesNature, 2013
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009